| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| KRYSKrystal Biotech, Inc. | 8.18B | 282.01 | 94.00 | 473.02% | 53.3% | 17.48% | 1.46% | 0.01 |
| BMRNBioMarin Pharmaceutical Inc. | 10.58B | 55.07 | 24.92 | 17.97% | 16.82% | 8.59% | 4.49% | 0.11 |
| SRPTSarepta Therapeutics, Inc. | 2.23B | 21.31 | 9.11 | 52.97% | -11.25% | -20.57% | 0.88 | |
| RAREUltragenyx Pharmaceutical Inc. | 2.27B | 23.50 | -3.74 | 29.01% | -91.95% | -35.88% | 0.15 | |
| DYNDyne Therapeutics, Inc. | 2.7B | 16.42 | -4.87 | -61.26% | 0.04 | |||
| TVTXTravere Therapeutics, Inc. | 2.54B | 28.40 | -6.96 | 60.55% | -20.32% | -120.36% | 6.80 | |
| BEAMBeam Therapeutics Inc. | 3.25B | 32.05 | -7.00 | -83.18% | -7.44% | -42.92% | 0.22 | |
| SLNOSoleno Therapeutics, Inc. | 2.25B | 41.95 | -9.58 | -79.5% | -15.85% | 0.22 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 6.04M | 16.48M | 26.12M | 30.43M | 43.1M | 57.99M | 33.05M | 52.12M | 36.27M | 57.88M |
| Revenue Growth % | - | 1.73% | 0.58% | 0.17% | 0.42% | 0.35% | -0.43% | 0.58% | -0.3% | 0.6% |
| Cost of Goods Sold | 11.17M | 31.84M | 67.65M | 89.11M | 108.41M | 150.41M | 6.89M | 7.57M | 8.98M | 10.29M |
| COGS % of Revenue | 1.85% | 1.93% | 2.59% | 2.93% | 2.52% | 2.59% | 0.21% | 0.15% | 0.25% | 0.18% |
| Gross Profit | -5.13M | -15.36M | -41.53M | -58.68M | -65.31M | -92.41M | 26.16M | 44.55M | 27.3M | 47.59M |
| Gross Margin % | -0.85% | -0.93% | -1.59% | -1.93% | -1.52% | -1.59% | 0.79% | 0.85% | 0.75% | 0.82% |
| Gross Profit Growth % | -2.09% | -2% | -1.7% | -0.41% | -0.11% | -0.42% | 1.28% | 0.7% | -0.39% | 0.74% |
| Operating Expenses | 19.45M | 48.64M | 95.67M | 121.3M | 41.06M | 44.17M | 294.01M | 502.71M | 542.59M | 581.86M |
| OpEx % of Revenue | 3.22% | 2.95% | 3.66% | 3.99% | 0.95% | 0.76% | 8.9% | 9.65% | 14.96% | 10.05% |
| Selling, General & Admin | 8.28M | 16.8M | 28.02M | 32.19M | 41.06M | 44.17M | 71.1M | 90.31M | 116.5M | 125.83M |
| SG&A % of Revenue | 1.37% | 1.02% | 1.07% | 1.06% | 0.95% | 0.76% | 2.15% | 1.73% | 3.21% | 2.17% |
| Research & Development | 11.17M | 31.84M | 67.65M | 89.11M | 108.41M | 150.41M | 229.81M | 419.98M | 435.07M | 466.31M |
| R&D % of Revenue | 1.85% | 1.93% | 2.59% | 2.93% | 2.52% | 2.59% | 6.95% | 8.06% | 11.99% | 8.06% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | -108.41M | -150.41M | -6.89M | -7.57M | -8.98M | -10.29M |
| Operating Income | -13.41M | -32.16M | -69.56M | -90.87M | -106.37M | -136.58M | -267.85M | -458.16M | -515.29M | -534.26M |
| Operating Margin % | -2.22% | -1.95% | -2.66% | -2.99% | -2.47% | -2.36% | -8.1% | -8.79% | -14.21% | -9.23% |
| Operating Income Growth % | -1.57% | -1.4% | -1.16% | -0.31% | -0.17% | -0.28% | -0.96% | -0.71% | -0.12% | -0.04% |
| EBITDA | -13.08M | -31.05M | -66.56M | -86.41M | -100.78M | -130.27M | -260.96M | -450.59M | -506.31M | -523.98M |
| EBITDA Margin % | -2.16% | -1.88% | -2.55% | -2.84% | -2.34% | -2.25% | -7.9% | -8.65% | -13.96% | -9.05% |
| EBITDA Growth % | -1.51% | -1.37% | -1.14% | -0.3% | -0.17% | -0.29% | -1% | -0.73% | -0.12% | -0.03% |
| D&A (Non-Cash Add-back) | 328K | 1.1M | 2.99M | 4.46M | 5.59M | 6.31M | 6.89M | 7.57M | 8.98M | 10.29M |
| EBIT | -13.41M | -32.16M | -69.56M | -90.87M | -106.37M | -136.58M | -267.85M | -458.16M | -515.29M | -534.26M |
| Net Interest Income | 0 | 525K | 2.01M | 5.53M | 6.83M | 2.35M | 1.28M | 8.54M | 49.83M | 47.81M |
| Interest Income | 0 | 525K | 2.01M | 5.53M | 6.83M | 2.35M | 1.28M | 8.54M | 49.83M | 47.81M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 0 | 525K | 2.01M | 5.53M | 6.83M | 2.35M | -42K | -16.02M | 34.1M | 15.24M |
| Pretax Income | -13.41M | -31.63M | -67.54M | -85.34M | -99.53M | -134.23M | -267.89M | -474.19M | -481.19M | -519.02M |
| Pretax Margin % | -2.22% | -1.92% | -2.59% | -2.8% | -2.31% | -2.31% | -8.1% | -9.1% | -13.27% | -8.97% |
| Income Tax | -1.01M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0.92% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -12.4M | -31.63M | -67.54M | -85.34M | -99.53M | -134.23M | -267.89M | -474.19M | -481.19M | -519.02M |
| Net Margin % | -2.05% | -1.92% | -2.59% | -2.8% | -2.31% | -2.31% | -8.1% | -9.1% | -13.27% | -8.97% |
| Net Income Growth % | 0.13% | -1.55% | -1.14% | -0.26% | -0.17% | -0.35% | -1% | -0.77% | -0.01% | -0.08% |
| Net Income (Continuing) | -12.4M | -31.63M | -67.54M | -85.34M | -99.53M | -134.23M | -267.89M | -474.19M | -481.19M | -519.02M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.70 | -0.91 | -1.88 | -1.98 | -1.96 | -2.40 | -3.78 | -6.16 | -5.42 | -5.25 |
| EPS Growth % | 0.5% | -0.3% | -1.07% | -0.05% | 0.01% | -0.22% | -0.57% | -0.63% | 0.12% | 0.03% |
| EPS (Basic) | -0.70 | -0.91 | -1.88 | -1.98 | -1.96 | -2.40 | -3.78 | -6.16 | -5.42 | -5.25 |
| Diluted Shares Outstanding | 17.66M | 34.62M | 36.01M | 43.07M | 47.25M | 55.99M | 70.89M | 76.97M | 88.77M | 98.85M |
| Basic Shares Outstanding | 17.66M | 34.62M | 36.01M | 43.07M | 47.25M | 55.99M | 70.89M | 76.97M | 88.77M | 98.85M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 77.63M | 281.31M | 354.83M | 324.98M | 289.48M | 616.52M | 769.3M | 1.22B | 998.33M | 639.86M |
| Cash & Short-Term Investments | 75.82M | 273.06M | 340.68M | 314.06M | 279.73M | 597.37M | 748.69M | 1.19B | 912.22M | 601.51M |
| Cash Only | 75.82M | 273.06M | 340.68M | 58.86M | 57.23M | 160.02M | 123.41M | 523.51M | 226.75M | 189.18M |
| Short-Term Investments | 0 | 0 | 0 | 255.2M | 222.5M | 437.35M | 625.28M | 669.12M | 685.48M | 412.33M |
| Accounts Receivable | 1M | 6.45M | 10.47M | 7.55M | 4.62M | 2.13M | 2.03M | 3.77M | 36.46M | 8.52M |
| Days Sales Outstanding | 60.39 | 142.95 | 146.34 | 90.51 | 39.12 | 13.41 | 22.43 | 26.39 | 366.82 | 53.71 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 1.79M | 3.68M | 3.37M | 0 | 0 | 0 | 20.41M | 49.65M | 29.83M |
| Total Non-Current Assets | 4.51M | 17.66M | 21.41M | 22.34M | 44.8M | 59.8M | 525.16M | 303.32M | 302.65M | 551.15M |
| Property, Plant & Equipment | 2.71M | 10.63M | 15.27M | 17.06M | 37.13M | 55.06M | 100.11M | 161M | 148.13M | 246.67M |
| Fixed Asset Turnover | 2.23x | 1.55x | 1.71x | 1.78x | 1.16x | 1.05x | 0.33x | 0.32x | 0.24x | 0.23x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 4.75M | 4.75M | 425.05M | 142.32M | 154.51M | 44.26M |
| Other Non-Current Assets | 1.8M | 7.04M | 6.13M | 5.28M | 2.92M | 0 | 0 | 0 | 0 | 260.21M |
| Total Assets | 82.14M | 298.97M | 376.24M | 347.31M | 334.28M | 676.32M | 1.29B | 1.52B | 1.3B | 1.19B |
| Asset Turnover | 0.07x | 0.06x | 0.07x | 0.09x | 0.13x | 0.09x | 0.03x | 0.03x | 0.03x | 0.05x |
| Asset Growth % | 6.68% | 2.64% | 0.26% | -0.08% | -0.04% | 1.02% | 0.91% | 0.17% | -0.14% | -0.08% |
| Total Current Liabilities | 10.7M | 30.73M | 31.36M | 40.57M | 35.63M | 64.25M | 125.83M | 126.55M | 115.21M | 110.85M |
| Accounts Payable | 1.36M | 4.65M | 2.17M | 2.71M | 3.94M | 10.46M | 9.65M | 5.15M | 7.45M | 14.59M |
| Days Payables Outstanding | 44.44 | 53.33 | 11.72 | 11.09 | 13.27 | 25.38 | 511.3 | 248.44 | 303.03 | 517.74 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K |
| Other Current Liabilities | 1.51M | 3.2M | 3.23M | 4.57M | 6.31M | 10.92M | 20.36M | 21.78M | 6.89M | 55.35M |
| Current Ratio | 7.26x | 9.15x | 11.32x | 8.01x | 8.12x | 9.59x | 6.11x | 9.61x | 8.67x | 5.77x |
| Quick Ratio | 7.26x | 9.15x | 11.32x | 8.01x | 8.12x | 9.59x | 6.11x | 9.61x | 8.67x | 5.77x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 4.09M | 58.4M | 44.28M | 28.82M | 28.77M | 85M | 128.39M | 157.98M | 135.6M | 208.21M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 12.63M | 33.61M | 64.91M | 114.02M | 96.75M | 189.95M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -38.85M | 0 |
| Other Non-Current Liabilities | 323K | 293K | 168K | 13K | 0 | 0 | 0 | 24.03M | 38.85M | 0 |
| Total Liabilities | 14.78M | 89.13M | 75.64M | 69.39M | 64.4M | 149.25M | 254.22M | 284.53M | 250.81M | 319.06M |
| Total Debt | 0 | 0 | 0 | 0 | 18.38M | 39.3M | 74.02M | 130.7M | 115.35M | 210.2M |
| Net Debt | -75.82M | -273.06M | -340.68M | -58.86M | -38.85M | -120.72M | -49.38M | -392.8M | -111.4M | 21.02M |
| Debt / Equity | - | - | - | - | 0.07x | 0.07x | 0.07x | 0.11x | 0.11x | 0.24x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - | - | - |
| Total Equity | 67.36M | 209.84M | 300.6M | 277.92M | 269.88M | 527.07M | 1.04B | 1.24B | 1.05B | 871.96M |
| Equity Growth % | 7.9% | 2.12% | 0.43% | -0.08% | -0.03% | 0.95% | 0.97% | 0.19% | -0.15% | -0.17% |
| Book Value per Share | 3.81 | 6.06 | 8.35 | 6.45 | 5.71 | 9.41 | 14.67 | 16.05 | 11.83 | 8.82 |
| Total Shareholders' Equity | 67.36M | 209.84M | 300.6M | 277.92M | 269.88M | 527.07M | 1.04B | 1.24B | 1.05B | 871.96M |
| Common Stock | 3K | 4K | 4K | 5K | 5K | 7K | 7K | 9K | 9K | 10K |
| Retained Earnings | -21.94M | -53.57M | -121.11M | -201.03M | -300.88M | -435.11M | -703M | -1.18B | -1.66B | -2.18B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -88.56M | 0 | 0 | -28K | 261K | 1K | -2.63M | -7.46M | -2.26M | 605K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -1.76M | 36.11M | -65.28M | -61.26M | -103.24M | -49.91M | -225.03M | -333.29M | -394.09M | -348.88M |
| Operating CF Margin % | -0.29% | 2.19% | -2.5% | -2.01% | -2.4% | -0.86% | -6.81% | -6.39% | -10.86% | -6.03% |
| Operating CF Growth % | 0.49% | 21.48% | -2.81% | 0.06% | -0.69% | 0.52% | -3.51% | -0.48% | -0.18% | 0.11% |
| Net Income | -12.4M | -31.63M | -67.54M | -85.34M | -99.53M | -134.23M | -267.89M | -474.19M | -481.19M | -519.02M |
| Depreciation & Amortization | 328K | 1.1M | 2.99M | 4.46M | 5.59M | 6.31M | 6.89M | 7.57M | 8.98M | 10.29M |
| Stock-Based Compensation | 1.31M | 6.71M | 15.32M | 17.05M | 15.09M | 19.9M | 47.01M | 91.4M | 134.05M | 154.27M |
| Deferred Taxes | -1.01M | -6.7M | 0 | 0 | 0 | 0 | 8.93M | 0 | 0 | 0 |
| Other Non-Cash Items | 9K | 6.71M | 166K | -601K | -3.72M | 573K | 2.94M | 95.8M | -3.47M | -6.29M |
| Working Capital Changes | 10M | 59.91M | -16.21M | 3.18M | -20.66M | 57.53M | -22.9M | -53.87M | -52.45M | 11.88M |
| Change in Receivables | -1.01M | -5.45M | -4.02M | 2.92M | 2.93M | 2.49M | 99K | -1.74M | -32.69M | 27.94M |
| Change in Inventory | 0 | -4.39M | 1.28M | 3.96M | 1.65M | 0 | 7.82M | 0 | 0 | 0 |
| Change in Payables | 335K | 1.78M | -488K | 232K | 1.88M | 5.06M | 529K | -4.58M | 2.52M | 6.8M |
| Cash from Investing | -2.55M | -6.17M | -10.09M | -260.78M | 25.18M | -214.49M | -550.78M | 160.31M | -31.35M | 125.57M |
| Capital Expenditures | -2.55M | -6.17M | -10.09M | -6.36M | -6.79M | -3.58M | -12.76M | -58.39M | -13.98M | -5.78M |
| CapEx % of Revenue | 0.42% | 0.37% | 0.39% | 0.21% | 0.16% | 0.06% | 0.39% | 1.12% | 0.39% | 0.1% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | -10.1K | 131K | 31.97M | 0 | 0 | 44.83M | 0 | 0 |
| Cash from Financing | 70.29M | 167.3M | 142.98M | 40.22M | 76.43M | 371.78M | 736.69M | 582.96M | 130.32M | 185.75M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | -1.7M | -3.1M | 1.98M | 11.67M | 4.18M | 13.13M | 43.12M | 17.17M | 10.53M | 8.85M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -4.32M | 29.94M | -75.37M | -67.61M | -110.03M | -53.5M | -237.79M | -391.68M | -408.07M | -354.66M |
| FCF Margin % | -0.71% | 1.82% | -2.89% | -2.22% | -2.55% | -0.92% | -7.19% | -7.51% | -11.25% | -6.13% |
| FCF Growth % | -0.11% | 7.94% | -3.52% | 0.1% | -0.63% | 0.51% | -3.44% | -0.65% | -0.04% | 0.13% |
| FCF per Share | -0.24 | 0.87 | -2.09 | -1.57 | -2.33 | -0.96 | -3.35 | -5.09 | -4.60 | -3.59 |
| FCF Conversion (FCF/Net Income) | 0.14x | -1.14x | 0.97x | 0.72x | 1.04x | 0.37x | 0.84x | 0.70x | 0.82x | 0.67x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -33.09% | -22.82% | -26.46% | -29.5% | -36.34% | -33.69% | -34.18% | -41.67% | -42.1% | -54% |
| Return on Invested Capital (ROIC) | - | - | - | -76.16% | -35.45% | -32.14% | -28.76% | -37.48% | -43.39% | -43.75% |
| Gross Margin | -84.81% | -93.22% | -159.02% | -192.81% | -151.52% | -159.35% | 79.15% | 85.47% | 75.26% | 82.23% |
| Net Margin | -205.11% | -191.97% | -258.62% | -280.42% | -230.92% | -231.46% | -810.49% | -909.78% | -1326.51% | -896.77% |
| Debt / Equity | - | - | - | - | 0.07x | 0.07x | 0.07x | 0.11x | 0.11x | 0.24x |
| FCF Conversion | 0.14x | -1.14x | 0.97x | 0.72x | 1.04x | 0.37x | 0.84x | 0.70x | 0.82x | 0.67x |
| Revenue Growth | - | 172.65% | 58.49% | 16.53% | 41.63% | 34.55% | -43.01% | 57.69% | -30.4% | 59.55% |
Intellia Therapeutics, Inc. (NTLA) reported $57.5M in revenue for fiscal year 2024.
Intellia Therapeutics, Inc. (NTLA) grew revenue by 59.6% over the past year. This is strong growth.
Intellia Therapeutics, Inc. (NTLA) reported a net loss of $445.8M for fiscal year 2024.
Intellia Therapeutics, Inc. (NTLA) has a return on equity (ROE) of -54.0%. Negative ROE indicates the company is unprofitable.
Intellia Therapeutics, Inc. (NTLA) had negative free cash flow of $412.6M in fiscal year 2024, likely due to heavy capital investments.